SCHEMBL1301629

SCHEMBL1301629

O=c1ccc(-c2cc(F)cc(F)c2)nn1Cc1cccc(-c2ncc(-c3cnn(C4CCNCC4)c3)o2)c1

nearest known ligand 0.61

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1302319 0.99 MET (0.60) MET
SCHEMBL3057786 0.89 MET (0.58) MET
SCHEMBL1301863 0.88 MET (0.60) MET
SCHEMBL3095911 0.86 MET (0.59) MET
SCHEMBL13153020 0.86 MET (0.62) MET
SCHEMBL1301970 0.86 MET (0.55) MET
SCHEMBL2479041 0.85 MET (0.54) MET
SCHEMBL1301308 0.84 MET (0.62) MET
SCHEMBL3059205 0.83 MET (0.70) MET
Hydrochloric Acid SCHEMBL3052522 0.83 MET (0.69) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623870-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-07 US claimed
EP-2373647-B1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-31 EP claimed
US-20110269771-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-11-03 US claimed
US-8623870-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-07 US disclosed
US-8623870-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-07 US disclosed
US-8623870-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-07 US disclosed
EP-2373647-B1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-31 EP disclosed
EP-2373647-B1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-31 EP disclosed
US-20110269771-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-11-03 US disclosed
US-20110269771-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-11-03 US disclosed
US-20110269771-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-11-03 US disclosed
EP-2373647-A1 PYRIDAZINONE DERIVATIVES Merck Patent GmbH (DE) 2011-10-12 EP disclosed
WO-2010078909-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2010-07-15 WO disclosed
WO-2010078909-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269771-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 MET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.